X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STRIDES SHASUN LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STRIDES SHASUN LTD GLENMARK PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 12.0 13.9 86.2% View Chart
P/BV x 3.2 1.6 196.5% View Chart
Dividend Yield % 0.4 0.6 62.1%  

Financials

 GLENMARK PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
STRIDES SHASUN LTD
Mar-17
GLENMARK PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs9931,275 77.9%   
Low Rs729918 79.4%   
Sales per share (Unadj.) Rs325.5389.6 83.6%  
Earnings per share (Unadj.) Rs39.328.0 140.5%  
Cash flow per share (Unadj.) Rs48.748.9 99.5%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.20.4 56.6%  
Book value per share (Unadj.) Rs159.2303.1 52.5%  
Shares outstanding (eoy) m282.1789.42 315.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.8 94.0%   
Avg P/E ratio x21.939.2 55.9%  
P/CF ratio (eoy) x17.722.4 78.9%  
Price / Book Value ratio x5.43.6 149.5%  
Dividend payout %5.116.1 31.6%   
Avg Mkt Cap Rs m242,99198,036 247.9%   
No. of employees `00013.05.8 223.6%   
Total wages/salary Rs m16,4085,881 279.0%   
Avg. sales/employee Rs Th7,083.96,005.9 117.9%   
Avg. wages/employee Rs Th1,265.41,014.0 124.8%   
Avg. net profit/employee Rs Th855.1431.2 198.3%   
INCOME DATA
Net Sales Rs m91,85734,834 263.7%  
Other income Rs m3741,686 22.2%   
Total revenues Rs m92,23036,520 252.5%   
Gross profit Rs m20,3676,428 316.8%  
Depreciation Rs m2,6441,872 141.3%   
Interest Rs m2,3732,269 104.6%   
Profit before tax Rs m15,7243,973 395.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m-810-1,006 80.5%   
Tax Rs m3,827470 814.2%   
Profit after tax Rs m11,0882,501 443.3%  
Gross profit margin %22.218.5 120.2%  
Effective tax rate %24.311.8 205.7%   
Net profit margin %12.17.2 168.1%  
BALANCE SHEET DATA
Current assets Rs m68,74638,165 180.1%   
Current liabilities Rs m27,02730,402 88.9%   
Net working cap to sales %45.422.3 203.8%  
Current ratio x2.51.3 202.6%  
Inventory Days Days8577 109.9%  
Debtors Days Days96104 91.4%  
Net fixed assets Rs m24,13237,639 64.1%   
Share capital Rs m282894 31.6%   
"Free" reserves Rs m44,64326,210 170.3%   
Net worth Rs m44,92527,105 165.7%   
Long term debt Rs m45,36316,377 277.0%   
Total assets Rs m117,63981,168 144.9%  
Interest coverage x7.62.8 277.2%   
Debt to equity ratio x1.00.6 167.1%  
Sales to assets ratio x0.80.4 181.9%   
Return on assets %11.45.9 194.7%  
Return on equity %24.79.2 267.5%  
Return on capital %19.112.1 158.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15213,465 417.0%   
Fx outflow Rs m8,0844,076 198.3%   
Net fx Rs m48,0689,389 511.9%   
CASH FLOW
From Operations Rs m6,5742,881 228.2%  
From Investments Rs m-7,124-7,051 101.0%  
From Financial Activity Rs m5,4323,382 160.6%  
Net Cashflow Rs m1,992-788 -253.0%  

Share Holding

Indian Promoters % 48.3 27.7 174.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 37.8 18.3%  
FIIs % 34.4 8.6 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   56,727 56,241 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and consumer durables sector witnessing maximum buying interest.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 20, 2018 01:39 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS